DK159689D0 - Medikeret hudplejepraeparat, dets fremstilling og anvendelse - Google Patents

Medikeret hudplejepraeparat, dets fremstilling og anvendelse

Info

Publication number
DK159689D0
DK159689D0 DK159689A DK159689A DK159689D0 DK 159689 D0 DK159689 D0 DK 159689D0 DK 159689 A DK159689 A DK 159689A DK 159689 A DK159689 A DK 159689A DK 159689 D0 DK159689 D0 DK 159689D0
Authority
DK
Denmark
Prior art keywords
manufacturing
skin care
care preparation
medicated skin
medicated
Prior art date
Application number
DK159689A
Other languages
English (en)
Other versions
DK159689A (da
Inventor
Navin Manohar Geria
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of DK159689D0 publication Critical patent/DK159689D0/da
Publication of DK159689A publication Critical patent/DK159689A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
DK159689A 1988-04-04 1989-04-03 Medikeret hudplejepraeparat, dets fremstilling og anvendelse DK159689A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/176,898 US4992478A (en) 1988-04-04 1988-04-04 Antiinflammatory skin moisturizing composition and method of preparing same

Publications (2)

Publication Number Publication Date
DK159689D0 true DK159689D0 (da) 1989-04-03
DK159689A DK159689A (da) 1989-10-05

Family

ID=22646344

Family Applications (1)

Application Number Title Priority Date Filing Date
DK159689A DK159689A (da) 1988-04-04 1989-04-03 Medikeret hudplejepraeparat, dets fremstilling og anvendelse

Country Status (13)

Country Link
US (1) US4992478A (da)
EP (1) EP0336902A3 (da)
JP (1) JPH0215022A (da)
KR (1) KR890015730A (da)
AU (1) AU615042B2 (da)
DK (1) DK159689A (da)
FI (1) FI891593A7 (da)
MX (1) MX166589B (da)
NO (1) NO891380L (da)
NZ (1) NZ228564A (da)
PH (1) PH25897A (da)
PT (1) PT90197B (da)
ZA (1) ZA892366B (da)

Families Citing this family (445)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9127062D0 (en) * 1991-12-20 1992-02-19 Unilever Plc Lip treatment composition
WO1994013257A1 (en) * 1992-12-16 1994-06-23 Creative Products Resource Associates, Ltd. Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder
JP3566739B2 (ja) * 1993-09-30 2004-09-15 三省製薬株式会社 皮膚外用剤の安定化方法
ATE395922T1 (de) 1994-08-29 2008-06-15 Univ Wake Forest Lipid-analoge zur behandlung von viralen infektionen
US7135584B2 (en) * 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
US5614489A (en) * 1995-05-25 1997-03-25 Mohammadi; Fatemeh Method and composition for treating the skin
FR2736827B1 (fr) * 1995-07-21 1997-09-19 Boucher Christine Bernard Huile cosmetique extraite des plantes du genre calophyllum
FR2737118B1 (fr) * 1995-07-28 1997-09-05 Oreal Composition dermatologique ou pharmaceutique, procede de preparation et utilisation
US5932553A (en) * 1996-07-18 1999-08-03 The Regents Of The University Of California Illudin analogs useful as antitumor agents
US5723632A (en) 1996-08-08 1998-03-03 Mgi Pharma, Inc. Total synthesis of antitumor acylfulvenes
DE19720083A1 (de) * 1997-05-14 1998-11-19 Silvia Zender Arzneimittel
CN1271341A (zh) * 1997-09-08 2000-10-25 乔治敦大学 Pkc的取代的2－吡咯烷酮激活剂
US6486214B1 (en) 1997-09-10 2002-11-26 Rutgers, The State University Of New Jersey Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby
ES2178301T3 (es) * 1997-12-29 2002-12-16 Res Corp Technologies Inc Derivados del acido penicilanico 2-beta-sustituido-6-alquilideno como inhibidores de la beta-lactama.
US6432941B1 (en) * 1998-01-20 2002-08-13 Parker Hughes Institute Vanadium compounds for treating cancer
US6245808B1 (en) 1998-11-05 2001-06-12 Parker Hughes Institute Oxy-vanadium (IV) complexes having spermicidal activity
US6051603A (en) 1998-01-20 2000-04-18 Wayne Hughes Institute Vanadium (IV) metallocene complexes having sperm motility inhibiting activity
US6025328A (en) 1998-02-20 2000-02-15 The Regents Of The University Of California Antitumor agents
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
DE19825856A1 (de) * 1998-06-10 1999-12-16 Labtec Gmbh Topische Arzneimittelzubereitung
US6355678B1 (en) * 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
US6800649B1 (en) 1998-06-30 2004-10-05 Parker Hughes Institute Method for inhibiting c-jun expression using JAK-3 inhibitors
AUPP583198A0 (en) * 1998-09-11 1998-10-01 Soltec Research Pty Ltd Mousse composition
US8263580B2 (en) * 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
JP3211027B2 (ja) * 1998-11-13 2001-09-25 丸石製薬株式会社 カプサイシン含有外用剤
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
AU759875B2 (en) 1999-03-09 2003-05-01 Pharmacia & Upjohn Company 4-OXO-4,7-dihydro-thieno(2,3-b)pyridine-5-carboxamides as antiviral agents
US6258820B1 (en) 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
US6306897B1 (en) 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
US6407091B1 (en) * 1999-04-15 2002-06-18 Research Corporation Technologies, Inc. β-lactamase inhibiting compounds
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
WO2000069470A2 (en) * 1999-05-17 2000-11-23 Aesgen, Inc. Improved cellular uptake of bioactive agents
WO2000078793A2 (en) * 1999-06-22 2000-12-28 University Of Louisville Research Foundation, Inc. Antimicrobial agents
US6670341B1 (en) 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
US7026469B2 (en) * 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
US6740650B2 (en) 1999-10-29 2004-05-25 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
AU1608801A (en) 1999-11-15 2001-05-30 Parker Hughes Institute Diamino platinum (ii) antitumor complexes
US6649654B1 (en) * 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors
US6589992B2 (en) 1999-11-30 2003-07-08 Parker Hughes Institute Inhibiting collagen-induced platelet aggregation
IL133968A0 (en) * 2000-01-10 2001-04-30 Thixo Ltd Therapeutic oils and edible pastes containing the same
US6967023B1 (en) * 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
NZ521523A (en) 2000-03-21 2004-05-28 Upjohn Co 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents
KR20020081480A (ko) 2000-03-21 2002-10-26 파마시아 앤드 업존 캄파니 항바이러스제로서의 4-히드록시신놀린-3-카르복시아미드
CN1416430A (zh) 2000-03-21 2003-05-07 法玛西雅厄普约翰美国公司 作为抗病毒药的4－氧－1,4－二氢[1,8]－二氮杂萘－3－甲酰胺类
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US6682892B2 (en) 2000-07-13 2004-01-27 Pharmacia & Upjohn Company Method for treating herpes viruses
US6696441B1 (en) 2000-08-11 2004-02-24 The Regents Of The University Of California Inhibition of p53-induced stress response
WO2002026762A1 (en) * 2000-09-29 2002-04-04 Regents Of The University Of Minnesota Triterpenes having antibacterial activity
EP1322661A1 (en) 2000-09-29 2003-07-02 Regents Of The University Of Minnesota Triterpenes having fungicidal activity against yeast
US6951847B2 (en) * 2000-09-29 2005-10-04 Regents Of The University Of Minnesota Methods of treating fungal infections using lupeol
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
US6958359B1 (en) * 2000-11-15 2005-10-25 Parker Hughes Institute Vanadium compounds as anti-angiogenic agents
US6878388B1 (en) 2000-11-15 2005-04-12 Parker Hughes Institute Vanadium compounds for treating proliferative cell disorders
US6642221B1 (en) 2000-11-15 2003-11-04 Parker Hughes Institute Vanadium compounds as anti-proliferative agents
AU2002249885A1 (en) 2000-11-17 2002-08-12 Adolor Corporation Delta agonist analgesics
US7250172B2 (en) * 2001-01-31 2007-07-31 University Of Iowa Research Foundation Vaccine and compositions for the prevention and treatment of neisserial infections
US7261901B2 (en) * 2001-01-31 2007-08-28 University Of Iowa Research Foundation Vaccine and compositions for the prevention and treatment of neisserial infections
US7232829B2 (en) * 2001-04-06 2007-06-19 Regents Of The University Of Minnesota Therapeutic compounds and methods
KR20030041130A (ko) * 2001-05-29 2003-05-23 코닌클리케 필립스 일렉트로닉스 엔.브이. 금속-세라믹 접착
US7601846B2 (en) * 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
US20030232794A1 (en) * 2001-06-26 2003-12-18 Cottam Howard B. Use of STAT-6 inhibitors as therapeutic agents
AU2002353768A1 (en) * 2001-07-24 2003-03-18 Alamx, L.L.C. 7-alkylidene-3-substituted-3-cephem-4-carboxylates as beta-lactamase inhibitors.
US20030171377A1 (en) * 2001-08-29 2003-09-11 Bigge Christopher Franklin Antidiabetic agents
US7551837B2 (en) * 2001-08-31 2009-06-23 Thomson Licensing Sequence counter for an audio visual stream
US20040116350A1 (en) * 2001-09-17 2004-06-17 Paul Wentworth Jr Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
US20050129680A1 (en) * 2001-09-17 2005-06-16 Paul Wentworth Antimicrobial activity of antibodies
US20040157280A1 (en) * 2001-09-17 2004-08-12 Paul Wentworth Antibody mediated ozone generation
CA2460911C (en) * 2001-10-01 2011-08-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
AU2002334969A1 (en) * 2001-10-09 2003-04-22 Sylvie Barchechath Use of stat-6 inhibitors as therapeutic agents
ES2340473T3 (es) 2001-11-14 2010-06-04 Rutgers, The State University Venenos de topoisomerasas solubilizadas.
AU2002357762A1 (en) 2001-11-23 2003-06-10 Theodore James Anastasion Improved synthesis of polyanhyrides
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
EP1517689A2 (en) * 2002-01-25 2005-03-30 Regents Of The University Of Minnesota Selective analgesic agents
US7022691B2 (en) * 2002-04-04 2006-04-04 John D. Buynak Inhibitors of serine and metallo-β-lactamases
AUPS158502A0 (en) * 2002-04-08 2002-05-16 Dermcare-Vet Pty Ltd Allergic dermatitis composition and method of treatment
US20090170803A1 (en) * 2002-04-10 2009-07-02 Linden Joel M Adjunctive treatment of biological diseases
US20040156799A1 (en) * 2002-06-04 2004-08-12 Zigang Dong Cancer treatment method and compositions
UA79293C2 (en) * 2002-07-03 2007-06-11 Univ Wayne State 4-(7'-halo-2-quino (xa-) linyloxy)phenoxy propionic acid derivatives as antineoplastic agents
CN1802152A (zh) 2002-08-01 2006-07-12 艾斯根公司 用谷氨酰胺改善癌症的治疗
US6989387B2 (en) * 2002-08-09 2006-01-24 Rutgers, The State University Of New Jersey Nitro and amino substituted topoisomerase agents
US7438918B2 (en) * 2002-08-30 2008-10-21 University Of Iowa Research Foundation Lipid A deficient mutants of Neisseria meningitidis
CA2497003A1 (en) * 2002-09-11 2004-03-25 Warner-Lambert Company Llc Inhibitors of factor xa and other serine proteases involved in the coagulation cascade
WO2004032599A2 (en) 2002-10-10 2004-04-22 Cornell Research Foundation, Inc. Novel immunogenic proteins of leptospira
EP1552025A4 (en) * 2002-10-18 2006-12-13 Cylene Pharmaceuticals Inc METHODS FOR IDENTIFYING TARGETED ANTIVIRAL MOLECULES TO QUADRUPLEX STRUCTURES
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US20060018937A1 (en) * 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9265725B2 (en) * 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US20050186142A1 (en) * 2002-10-25 2005-08-25 Foamix Ltd. Kit and composition of imidazole with enhanced bioavailability
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20080206161A1 (en) * 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US20050205086A1 (en) * 2002-10-25 2005-09-22 Foamix Ltd. Retinoid immunomodulating kit and composition and uses thereof
JP2006505583A (ja) * 2002-10-25 2006-02-16 フォーミックス エルティーディー． 化粧剤および医薬用フォーム
US8486376B2 (en) * 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US20060193789A1 (en) * 2002-10-25 2006-08-31 Foamix Ltd. Film forming foamable composition
US20050271596A1 (en) * 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US7544674B2 (en) 2002-10-25 2009-06-09 Galderma S.A. Topical skin care composition
US8119109B2 (en) * 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US20070292355A1 (en) * 2002-10-25 2007-12-20 Foamix Ltd. Anti-infection augmentation foamable compositions and kit and uses thereof
US20070292359A1 (en) * 2002-10-25 2007-12-20 Foamix Ltd. Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
US20080317679A1 (en) * 2002-10-25 2008-12-25 Foamix Ltd. Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
JP2006520584A (ja) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． 安定化単一ドメイン抗体
EP1563299A2 (en) * 2002-11-14 2005-08-17 Novartis AG Antibody- or neutrophil-mediated ozone generation
US7297340B2 (en) * 2003-01-07 2007-11-20 University Of Iowa Research Foundation Vaccine and method for preventing biofilm formation
BRPI0406694B8 (pt) 2003-01-10 2021-05-25 Ablynx Nv polipeptídios terapêutico, seus homólogos, seus fragmentos, que são usados nas modulações da agregação plaquetária
US20050079512A1 (en) * 2003-02-26 2005-04-14 Emerson Beverly M. Methods of modulating gene expression
US7354916B2 (en) * 2003-04-07 2008-04-08 Cylene Pharmaceuticals Substituted quinobenzoxazine analogs
WO2004091627A2 (en) * 2003-04-07 2004-10-28 Cylene Pharmaceuticals, Inc. Heterocyclic substituted 1,4-dihydro-4-oxo-1,8-naphthpyridine analogs
US7507727B2 (en) * 2003-04-07 2009-03-24 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs and methods of using thereof
WO2004091504A2 (en) 2003-04-07 2004-10-28 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
PT1653943E (pt) 2003-06-25 2008-05-23 Burnham Inst Derivados de catecol para o tratamento do cancro
WO2005003140A1 (en) * 2003-07-02 2005-01-13 Pharmacia & Upjohn Company Llc 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents
US20070140999A1 (en) * 2003-07-18 2007-06-21 Hill Dermaceuticals, Inc. Topical skin care composition containing refined peanut oil
CA2541373A1 (en) * 2003-07-18 2005-02-03 Hill Dermaceuticals, Inc. Topical skin care composition containing refined peanut oil
US8486374B2 (en) * 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
RU2357969C2 (ru) 2003-08-25 2009-06-10 АДЕНОЗАЙН ТЕРАПЬЮТИКС, ЭлЭлСи Новые замещенные 8-гетероарилксантины и фармацевтическая композиция на их основе
US9532994B2 (en) 2003-08-29 2017-01-03 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
US20060099173A1 (en) * 2003-10-24 2006-05-11 Nancy Puglia Topical skin care composition
EP1687338B1 (en) 2003-11-07 2010-10-20 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses thereof
AU2004305075A1 (en) * 2003-12-19 2005-07-07 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies
ZA200507017B (en) * 2004-02-04 2007-03-28 Foamix Ltd Cosmetic and pharmaceutical foam with solid matter
WO2005077377A1 (en) * 2004-02-06 2005-08-25 Regents Of The University Of Minnesota Compositions that include a triterpene and a carrier
CN1956966B (zh) 2004-02-19 2012-04-18 雷克斯安公司 喹唑啉衍生物及其治疗用途
US20050187192A1 (en) * 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
US20050187191A1 (en) * 2004-02-20 2005-08-25 Kucera Louis S. Methods and compositions for the treatment of respiratory syncytial virus
NZ550102A (en) * 2004-02-24 2010-10-29 Univ California Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
LT2574341T (lt) 2004-03-29 2017-09-11 University Of South Florida Navikų ir vėžio efektyvus gydymas triciribino fosfatu
WO2006028618A1 (en) * 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
SG155182A1 (en) 2004-08-02 2009-09-30 Univ Virginia 2-propynyl adenosine analogs with modified 5æ-ribose groups having a2a agonist activity
ES2517840T3 (es) * 2004-08-25 2014-11-04 University Of Iowa Research Foundation Inhibidores de la geranilgeranil pirofosfato sintasa
US7718680B2 (en) * 2004-09-23 2010-05-18 Burnham Institute For Medical Research Inhibition of lethal factor protease activity from anthrax toxin
RU2007117752A (ru) * 2004-10-13 2008-11-20 Аблинкс Н.В. (Be) Нанотела (nanobodies тм) против бета-амилоида и полипептидов, содержащих бета-амилоид, для лечения нейродегенеративных заболеваний, таких как болезнь альцгеймера
US8697674B2 (en) 2004-12-29 2014-04-15 Naturon, Inc. Xanthurenic acid derivative pharmaceutical compositions and methods related thereto
CA2594542C (en) * 2005-01-10 2014-03-25 University Of Virginia Patent Foundation Synthesis of inhibitors of p90rsk
EP1893396A2 (en) * 2005-05-09 2008-03-05 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
KR101579701B1 (ko) 2005-05-13 2015-12-22 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
EP2479191A3 (en) 2005-05-18 2013-03-13 Ablynx N.V. Improved nanobodiesTM against tumor necrosis factor-alpha
ES2852423T3 (es) 2005-05-20 2021-09-13 Ablynx Nv NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
JP5612263B2 (ja) * 2005-06-01 2014-10-22 スティーフェル リサーチ オーストラリア ピーティーワイ リミテッド ビタミン製剤
US20080152596A1 (en) * 2005-07-19 2008-06-26 Foamix Ltd. Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
JP4989648B2 (ja) * 2005-08-03 2012-08-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗癌剤として有用なイルジン類似体
ES2577514T3 (es) 2005-08-22 2016-07-15 The Regents Of The University Of California Antagonistas de TLR
US20070098667A1 (en) * 2005-10-27 2007-05-03 Jim Taneri Methods and compositions for epilation
US20070098660A1 (en) * 2005-10-27 2007-05-03 Jim Taneri Methods and compositions for epilation
WO2007056113A2 (en) * 2005-11-02 2007-05-18 Cylene Pharmaceuticals, Inc. Methods for targeting quadruplex sequences
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
EP1993558B1 (en) 2006-02-27 2014-07-30 The Regents of The University of California Oxysterol compounds and the hedgehog pathway
EP2007383A4 (en) * 2006-03-22 2010-09-15 Univ California HEMMER OF PROTEIN PRENYL TRANSFERASES
DK2656842T3 (da) * 2006-03-27 2016-11-07 Univ California Androgen receptormodulator til behandling af prostatacancer og androgene receptor-associerede sygdomme
EP3020706A1 (en) 2006-03-29 2016-05-18 The Regents Of The University Of California Diarylthiohydantoin compounds useful for the treatment of a hyperproliferative disorder
US8093235B2 (en) 2006-04-25 2012-01-10 Rutgers, The State University Of New Jersey Macrocyclic compounds which stabilize G-Quadruplex DNA and RNA
WO2007139778A2 (en) * 2006-05-22 2007-12-06 University Of Virginia Patent Foundation Rhamnose substituents of sl0101 and therapeutic uses thereof
WO2007146813A2 (en) * 2006-06-08 2007-12-21 Cylene Pharmaceuticals, Inc. Pyridinone analogs as cell proliferation inhibitors
US20100305136A1 (en) * 2006-06-08 2010-12-02 Johnny Yasuo Nagasawa Quinolone analogs derivatized with sulfonic acid, sulfonate or sulfonamide
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
CN101563058A (zh) * 2006-09-08 2009-10-21 弗米克斯有限公司 有色的或可着色的能起泡的组合物和泡沫
AU2007356328A1 (en) * 2006-11-14 2009-01-15 Tal Berman Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8034829B2 (en) 2006-11-17 2011-10-11 Rexahn Pharmaceuticals, Inc. 5, 6, or 7-substituted-3-(hetero)arylisoquinolinamine derivatives and therapeutic use thereof
WO2008065503A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. (r) -5-methyl-4, 5-dihydro- pyrazole-1, 5-dicarboxylic acid 1- [ ( 4 -chlorophenyl) amide 5-{ [2-fluoro-4- (2-oxo-2h-pyridin-1-yl) -phenyl]amide) as a factor xa inhibitor
EP2115004A2 (en) 2006-12-19 2009-11-11 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
AU2007336243B2 (en) 2006-12-19 2012-07-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
AU2008213666B2 (en) 2007-02-06 2013-11-07 University Of Louisville Research Foundation, Inc. Substituted alkine derivatives as anti-cancer agents
EA019151B1 (ru) 2007-02-07 2014-01-30 Дзе Регентс Оф Дзе Юниверсити Оф Калифорния Конъюгаты синтетических агонистов tlr и их применение
WO2008103818A1 (en) * 2007-02-21 2008-08-28 University Of Louisville Research Foundation Therapeutic cotinine compositions
WO2009073186A1 (en) 2007-12-03 2009-06-11 The Regents Of The University Of California Oxsterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling
US8569449B2 (en) 2007-05-08 2013-10-29 University Of Louisville Research Foundation, Inc. Synthetic peptides and peptide mimetics
WO2009009793A2 (en) 2007-07-12 2009-01-15 University Of South Florida Inhibitors of akt/pkb with anti-tumor activity
MX2010001303A (es) 2007-08-02 2010-09-07 Univ Rutgers Compuestos terapeuticos.
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009046383A1 (en) 2007-10-05 2009-04-09 Cylene Pharmaceuticals, Inc. Quinolone analogs and methods related thereto
CA2703724C (en) * 2007-10-19 2017-07-11 Burnham Institute Of Medical Research Naphthalene-based inhibitors of anti-apoptotic proteins
WO2009055677A1 (en) * 2007-10-24 2009-04-30 University Of South Florida Antibacterial s-heterosubstituted disulfides
EP2220050A2 (en) 2007-10-26 2010-08-25 The Regents Of The University Of California Diarylhydantoin compounds as androgen receptor modulators
US20090130029A1 (en) * 2007-11-21 2009-05-21 Foamix Ltd. Glycerol ethers vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
CA2712120A1 (en) * 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US8142764B2 (en) 2008-02-27 2012-03-27 University Of Louisville Research Foundation Synthetic biofilm-inhibiting peptides
WO2009114539A2 (en) * 2008-03-10 2009-09-17 University Of Louisville Research Foundation Neuroprotective integrin-binding peptide and angiopoietin-1 treatments
WO2009114921A1 (en) * 2008-03-17 2009-09-24 Dmitrienko Gary I INHIBITORS OF CLASS B AND CLASS D β-LACTAMASES
WO2009146112A1 (en) * 2008-04-02 2009-12-03 University Of Virginia Patent Foundation Compositions and methods for inhibiting sphingosine kinase
JP2011516520A (ja) 2008-04-07 2011-05-26 アブリンクス エン．ヴェー． Ｎｏｔｃｈ経路に指向性を有するアミノ酸配列及びその使用
RU2527561C2 (ru) 2008-04-16 2014-09-10 Говард Юнивесити Ингибиторы протеинфосфатазы-1 и их применение
CN102099378B (zh) 2008-05-16 2016-01-20 埃博灵克斯股份有限公司 针对CXCR4和其他GPCRs的氨基酸序列以及包含所述氨基酸序列的多肽
US9872867B2 (en) * 2008-06-06 2018-01-23 Tanya Kuritz Methods and compositions for modulation of innate immunity
US8673910B2 (en) * 2008-06-30 2014-03-18 H. Lee Moffitt Cancer Center And Research Institute Proteasome inhibitors for selectively inducing apoptosis in cancer cells
US20090324506A1 (en) * 2008-06-30 2009-12-31 Jeffery Richard Seidling Sprayable skin protectant formulation and method of use
US7947717B2 (en) * 2008-07-18 2011-05-24 Burnham Institute For Medical Research Inhibitors of lethal factor protease
WO2010011666A2 (en) * 2008-07-21 2010-01-28 University Of South Florida Indoline scaffold shp-2 inhibitors and cancer treatment method
US20110178138A1 (en) * 2008-07-28 2011-07-21 The Regents Of The University Of California Inhibitors of protein prenyltransferases
US9125821B2 (en) 2008-07-28 2015-09-08 The Regents Of The University Of California Nanodrug targeting protein geranylgeranylation
KR20110068993A (ko) 2008-08-05 2011-06-22 유니버시티 오브 사우스 플로리다 인지장애의 치료방법
US9132168B2 (en) 2008-08-05 2015-09-15 University Of South Florida Methods of treating cognitive impairment
AU2009279400A1 (en) * 2008-08-08 2010-02-11 University Of Florida Research Foundation, Inc. Lipid compounds for supression of tumorigenesis
US9480691B1 (en) * 2009-01-20 2016-11-01 Hill Dermaceuticals, Inc. Topical liquid containing refined peanut oil for treating skin proliferation or inflammation disorders
TW201038578A (en) 2009-01-30 2010-11-01 Univ Rutgers Methods to treat cancer
EP2408447A1 (en) 2009-03-20 2012-01-25 University of Iowa Research Foundation Prenylated bisphosphonates as anti-tuberculosis agents
CN105399828B (zh) 2009-04-10 2021-01-15 埃博灵克斯股份有限公司 用于治疗il-6r相关疾病和病症的改进的针对il-6r的氨基酸序列和包含其的多肽
CN102395268A (zh) 2009-04-15 2012-03-28 桑福德-伯纳姆医学研究院 基于萘的抗凋亡蛋白抑制剂
US8487131B2 (en) 2009-04-15 2013-07-16 Sanford-Burnham Medical Research Institute Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2)
WO2010125470A2 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
EP2430016B1 (en) 2009-05-13 2020-04-01 University Of Virginia Patent Foundation Inhibitors of inv(16) leukemia
MX2012000113A (es) 2009-06-30 2012-02-29 Forest Lab Holdings Ltd Compuestos alcoxi-carbonil-amino-alquinil-adenosina y derivados de los mismos como agonistas a2ar.
WO2011005871A1 (en) 2009-07-07 2011-01-13 Pgxhealth, Llc Substituted 8-[6-carbonylamine-3-pyridyl]xanthines as adenosine a2b antagonists
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
TW201107330A (en) 2009-07-31 2011-03-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
WO2011019995A2 (en) 2009-08-14 2011-02-17 Hecht Sidney M Synthesis and identification of novel rsk-specific inhibitors
TW201111385A (en) 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
US8642088B2 (en) 2009-09-04 2014-02-04 Wisconsin Alumni Research Foundation Tannin-chitosan composites
MX359879B (es) 2009-10-02 2018-10-12 Foamix Pharmaceuticals Ltd Composiciones tópicas de tetraciclina.
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
WO2011044375A2 (en) * 2009-10-08 2011-04-14 Sanford-Burnham Medical Research Institute Apogossypolone derivatives as anticancer agents
EP2496704A4 (en) 2009-11-05 2013-05-01 Univ Rutgers THERAPEUTIC COMPOUNDS
JP2013515740A (ja) 2009-12-23 2013-05-09 バイオクライスト ファーマシューティカルズ， インコーポレイテッド Ｊａｎｕｓキナーゼインヒビターとしての複素環式化合物
US9096544B2 (en) 2009-12-23 2015-08-04 Wayne State University Therapeutic compounds
AU2011218173C1 (en) 2010-02-16 2015-04-16 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
WO2011103686A1 (en) 2010-02-26 2011-09-01 Viswanatha , Sundaramma CEPHALOSPORIN DERIVATIVES USEFUL AS β-LACTAMASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF
CN103108861A (zh) 2010-04-02 2013-05-15 Tsrl公司 神经氨酸酶抑制剂
US9221808B2 (en) 2010-04-16 2015-12-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinase (ROCK) and methods of use
WO2011133696A2 (en) 2010-04-20 2011-10-27 Regents Of The University Of Minnesota Methods of suppressing atherosclerosis
MX2012013824A (es) 2010-05-28 2013-03-12 Biocryst Pharm Inc Compuestos heterociclicos como inhibidores de cinasa janus.
WO2012027494A1 (en) 2010-08-24 2012-03-01 Regents Of The University Of Minnesota Bispecific targeting reagents
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
DK2618811T3 (da) 2010-09-20 2015-04-07 Oréal L Vandig kosmetiksammensætning, der omfatter alkylcellulose
DK2618803T3 (da) 2010-09-20 2016-05-30 Oréal L Vandig kosmetisk sammensætning, der omfatter alkylcellulose
EP2632481A1 (en) 2010-10-25 2013-09-04 Regents Of The University Of Minnesota Therapeutic composition for treatment of glioblastoma
HUE031658T2 (en) 2011-02-07 2017-07-28 Biogen Ma Inc S1p modulating agents
EP2683837A2 (en) 2011-03-07 2014-01-15 University Of Louisville Research Foundation, Inc. Predictive marker of dnmt1 inhibitor therapeutic efficacy and methods of using the marker
US9616064B2 (en) 2011-03-30 2017-04-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Rho kinase inhibitors and methods of use
MX356426B (es) 2011-04-04 2018-05-29 Univ Iowa Res Found Metodos para mejorar inmunogenicidad de vacuna.
EP2694079B1 (en) 2011-04-06 2018-01-17 Rutgers, The State University of New Jersey Polymers and methods for the treatment of pain
US20120270860A1 (en) 2011-04-19 2012-10-25 Gihyun Yoon Methods for treating or preventing alcohol-related disorders or craving-related disorders
WO2012145678A1 (en) 2011-04-20 2012-10-26 Regents Of The University Of Minnesota Anti-cancer and anti-inflammatory parthenolide compounds
US9415112B2 (en) 2011-06-20 2016-08-16 Rutgers, The State University Of New Jersey Bipartite inhibitors of bacterial RNA polymerase
WO2013009647A1 (en) 2011-07-08 2013-01-17 Regents Of The University Of Minnesota Glutathione analogs and uses thereof
EP2734519B1 (en) 2011-07-22 2016-05-04 University Of Louisville Research Foundation, Inc. Anti-biofilm compounds
BR112014002200A2 (pt) 2011-07-29 2017-03-07 Medivation Prostate Therapeutics Inc tratamento de câncer de mama
WO2013028866A1 (en) 2011-08-24 2013-02-28 Regents Of The University Of Minnesota Therapeutic compounds and methods
US9034336B2 (en) 2011-08-30 2015-05-19 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
EP2750508A4 (en) 2011-08-30 2015-01-14 Univ Wayne State THERAPEUTIC COMPOUNDS AND METHOD
JP6258202B2 (ja) 2011-09-08 2018-01-10 ウェスタン ユニバーシティ オブ ヘルス サイエンス がん療法における標的リポソーム
CA2848540A1 (en) 2011-09-15 2013-03-21 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Therapeutic compounds
US9828326B2 (en) * 2011-12-27 2017-11-28 Northeast Ohio Medical University Amooranin compounds and analogs thereof and related methods of use
FR2985176B1 (fr) 2012-01-02 2015-05-29 Oreal Composition cosmetique liquide aqueuse comprenant de l'alkylcellulose, des huiles non volatiles et au moins un tensioactif
WO2013103969A1 (en) 2012-01-05 2013-07-11 Rutgers, The State University Of New Jersey Antibacterial agents: phloroglucinol derivatives
JP2015504674A (ja) 2012-01-11 2015-02-16 アリゾナ ボード オブ リージェンツ ア ボディ コーポレート オブ ザ ステイト オブ アリゾナ アクティング フォー アンド オン ビハーフ オブ アリゾナ ステイト ユニバーシティーＡｒｉｚｏｎａ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ， Ａ Ｂｏｄｙ Ｃｏｒｐｏｒａｔｅ Ｏｆ Ｔｈｅ Ｓｔａｔｅ Ｏｆ Ａｒｉｚｏｎａ Ａｃｔｉｎｇ Ｆｏｒ Ａｎｄ Ｏｎ Ｂｅｈａｌｆ Ｏｆ Ａｒｉｚｏｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ 神経疾患タンパク質の二重特異性抗体フラグメントおよび使用方法
US8947424B2 (en) 2012-01-17 2015-02-03 Eastman Kodak Company Spectral stereoscopic projection system
WO2013110077A1 (en) 2012-01-19 2013-07-25 Hybrid Medical, Llc Topical therapeutic formulations
EP2804852A2 (en) 2012-01-20 2014-11-26 Regents Of The University Of Minnesota Therapeutic compounds
WO2013113102A1 (en) 2012-02-01 2013-08-08 The Governors Of The University Of Alberta USE OF PDGFR-α AS DIAGNOSTIC MARKER FOR PAPILLARY THYROID CANCER
US20130195752A1 (en) 2012-02-01 2013-08-01 Regents Of The University Of Minnesota Functionalized nanoparticles and methods of use thereof
US9839634B2 (en) 2012-02-06 2017-12-12 Rutgers, The State University Of New Jersey Antibacterial agents: combination of a rifamycin and a switch region inhibitor
WO2013119946A1 (en) 2012-02-08 2013-08-15 Of Virginia Patent Foundation University Long chain base sphingosine kinase inhibitors
WO2013142812A1 (en) 2012-03-22 2013-09-26 Rutgers, The State University Of New Jersey Antibacterial agents: sidechain-fluorinated myxopyronin derivatives
WO2013148584A1 (en) 2012-03-26 2013-10-03 University Of Iowa Research Foundation Schweinfurthin analogues
US9340501B2 (en) 2012-04-16 2016-05-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Marinopyrrole derivatives as anticancer agents
US9272016B2 (en) 2012-04-20 2016-03-01 University Of Iowa Research Foundation Methods to enhance RNAi oligonucleotide delivery to respiratory epithelial cells
CN104395331B (zh) 2012-05-07 2016-11-02 加利福尼亚大学董事会 诱导骨生成和hedgehog 信号传导且抑制脂肪形成的氧固醇类似物氧固醇化合物133
EP2861570B1 (en) 2012-06-19 2018-07-18 Rutgers, The State University of New Jersey Antibacterial agents: aryl myxopyronin derivatives
ES2784223T3 (es) 2012-06-20 2020-09-23 Univ Virginia Patent Foundation Composiciones y procedimientos para regular la homeostasis de glucosa y la acción de insulina
US9669115B2 (en) 2012-06-29 2017-06-06 University Of Iowa Research Foundation Co-crystals and salts of contrast agents and imaging
US9745331B2 (en) 2012-07-05 2017-08-29 University Of Iowa Research Foundation Therapeutic bisphosphonates
CA2879460C (en) 2012-07-18 2021-10-19 Garrett MORASKI 5,5-heteroaromatic anti-infective compounds
WO2014018671A1 (en) 2012-07-24 2014-01-30 Regents Of The University Of Minnesota Therapeutic compounds for the treatment of cancer
ES2668694T3 (es) 2012-07-27 2018-05-21 Biogen Ma Inc. Derivados de ácido 1-[7-(cis-4-metil-ciclohexiloxi)-8-trifluorometil-naftalen-2-ilmetil]-piperidin-4-carboxílico como moduladores de autotaxina (ATX) para tratar inflamaciones y trastornos autoinmunitarios
BR112015002249A2 (pt) 2012-08-01 2017-07-04 Lewis And Clark Pharmaceuticals Inc composto, um estereoisômero ou sal farmaceuticamente aceitável do mesmo; composição farmacêutica; método para tratar um estado associado a receptor de adenosina a2a em um indivíduo; método para diagnosticar anormalidades de perfusão de miocárdio em um mamífero; e método para reduzir a pressão interocular em um indivíduo
US9249116B2 (en) 2012-08-03 2016-02-02 The Board Of Trustees Of The University Of Illinois Enzyme-activating compounds and compositions
ES2660287T3 (es) 2012-08-06 2018-03-21 Biogen Ma Inc. Compuestos que son agentes moduladores de s1p y/o agentes moduladores de atx
ES2691793T3 (es) 2012-08-06 2018-11-28 Biogen Ma Inc. Derivados de naftaleno 1,5,6-sustituidos como moduladores de receptor de 1-fosfato de esfingosina (S1P) y/o autotaxina (ATX) para tratar trastornos inflamatorios y autoinmunitarios
CA2881554C (en) 2012-08-22 2022-01-04 Cornell University Methods for inhibiting fascin
WO2014039860A2 (en) 2012-09-07 2014-03-13 University Of Louisville Research Foundation, Inc. Compositions and methods for modulating dnmt1 inhibitor activity
WO2014043252A2 (en) 2012-09-11 2014-03-20 Rutgers, The State University Of New Jersey Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones
IL312316A (en) 2012-09-26 2024-06-01 Aragon Pharmaceuticals Inc Antiandrogens for the treatment of castration-resistant prostate cancer without metastases
US9957214B2 (en) 2012-10-10 2018-05-01 Arizona Board Of Regents On Behalf Of Arizona State University Multifunctional radical quenchers
US9364406B2 (en) 2012-10-12 2016-06-14 Regents Of The University Of Minnesota Open chained or fused 1,1′-alkylene-bis-uracil derivatives, useful in skin UV-protection
WO2014066840A1 (en) 2012-10-26 2014-05-01 Regents Of The University Of Minnesota Aurora kinase inhibitors
WO2014070774A1 (en) 2012-10-29 2014-05-08 Southern Methodist University Methods of generating beta-lactamase resistant carbapenem compounds
WO2014074926A1 (en) 2012-11-09 2014-05-15 Rutgers, The State University Of New Jersey Therapeutic hydroxyquinolones
HK1212235A1 (en) 2012-11-16 2016-06-10 Biocryst Pharmaceuticals, Inc. Antiviral azasugar-containing nucleosides
US9670199B2 (en) 2012-11-19 2017-06-06 Regents Of The University Of Minnesota Ergoline derivatives as dopamine receptor modulators
EP2925721B1 (en) 2012-11-20 2017-06-07 Biogen MA Inc. S1p and/or atx modulating agents
ES2749467T3 (es) 2012-11-20 2020-03-20 Biogen Ma Inc Agentes moduladores de S1p y/o ATX
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
US9700044B2 (en) 2013-01-22 2017-07-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Symmetrical marinopyrrole derivatives as potential antibiotic agents
US9765016B2 (en) 2013-01-29 2017-09-19 Biogen Ma Inc. S1P modulating agents
US9981043B2 (en) 2013-02-08 2018-05-29 Regents Of The University Of Minnesota Analgesic conjugates
US9776975B2 (en) 2013-03-05 2017-10-03 University Of Notre Dame Du Lac Quinazolinone antibiotics
WO2014152725A1 (en) 2013-03-15 2014-09-25 Biogen Idec Ma Inc. S1p and/or atx modulating agents
US9387250B2 (en) 2013-03-15 2016-07-12 Rutgers, The State University Of New Jersey Therapeutic compositions for bone repair
US9617282B2 (en) 2013-03-15 2017-04-11 Biogen Ma Inc. Macrocyclic compounds as IRAK4 inhibitors for the treatment of inflammatory diseases
US20160024504A1 (en) 2013-03-15 2016-01-28 Constellation Pharmaceuticals, Inc. Treating th2-mediated diseases by inhibition of bromodomains
EP2991652A4 (en) 2013-05-02 2016-12-07 Univ California BONE-LAYERED BONE-RELATED OSTEOGENIC OXYSTEROL AGENTS
US9862672B2 (en) 2013-05-29 2018-01-09 Rutgers, The State University Of New Jersey Antioxidant-based poly(anhydride-esters)
US9987211B2 (en) 2013-07-03 2018-06-05 Regents Of The University Of Minnesota Sunless tanning compounds and compositions
CN105592850B (zh) 2013-08-06 2019-11-15 H·李·莫菲特癌症中心研究所公司 Ack1/tnk2酪氨酸激酶的抑制剂
EP3068416A4 (en) 2013-11-11 2017-08-09 Kuality Herbceutics LLC Kava derived therapeutic compounds and methods of use thereof
US9339482B2 (en) 2013-11-22 2016-05-17 Regents Of The University Of Minnesota Methods to treat dysregulated blood glucose disorders
US9315523B2 (en) 2013-12-06 2016-04-19 Rutgers, The State University Of New Jersey Cyclic dinucleosides
US9919998B2 (en) 2014-02-06 2018-03-20 Rutgers, The State University Of New Jersey Antibacterial agents: Nα-aroyl-N-aryl-phenylalaninamides
DK3107902T3 (da) 2014-02-20 2021-05-03 Cornell Univ Cornell Center For Technology Enterprise & Commercialization Cctec Forbindelser og fremgangsmåder til at hæmme fascin
WO2015130805A1 (en) 2014-02-26 2015-09-03 Arizona Board Of Regents On Behalf Of Arizona State University Dna gridiron compositions and methods
US10272055B2 (en) 2014-03-06 2019-04-30 Regents Of The University Of Minnesota Therapeutic compounds and methods
LT3828173T (lt) 2014-03-07 2022-11-10 Biocryst Pharmaceuticals, Inc. Pakeistieji pirazolai kaip žmogaus plazmos kalikreino inhibitoriai
US10197575B2 (en) 2014-03-31 2019-02-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Stabilized peptoid-peptide hybrids and uses thereof
WO2015166355A2 (en) 2014-04-18 2015-11-05 The Governors Of The University Of Alberta Targeted therapy to restore radioactive iodine transport in thyroid cancer
US9556113B2 (en) 2014-04-29 2017-01-31 The South Dakota Board Of Regents Combination uses of dichloroacetate and oxamate, and their prodrugs, for cancer treatment
CN106232612B (zh) 2014-05-02 2019-01-29 加利福尼亚大学董事会 骨选择性成骨性氧固醇双膦酸盐类似物
US9987299B2 (en) 2014-05-05 2018-06-05 University Of Iowa Research Foundation Methods of improving RNAi in well-differentiated airway epithelia
US10144732B2 (en) 2014-06-06 2018-12-04 Biogen Ma Inc. ATX modulating agents
WO2015195563A1 (en) 2014-06-16 2015-12-23 Rutgers, The State University Of New Jersey Antibacterial agents
US9737598B2 (en) 2014-06-30 2017-08-22 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
KR102299276B1 (ko) * 2014-07-16 2021-09-09 (주)아모레퍼시픽 납떼기콩 오일을 포함하는 조성물
CA2957691C (en) 2014-08-19 2023-10-31 Marvin J. Miller Antibacterial sideromycins
CA2964239C (en) 2014-09-11 2022-12-13 University Of Iowa Research Foundation Thymol and carvacol for use in medicine
WO2016076929A1 (en) 2014-11-13 2016-05-19 University Of Iowa Research Foundation Methods to generate epithelial cells
CA2976776C (en) 2015-02-17 2023-06-20 Arizona Board Of Regents On Behalf Of Arizona State University Phenothiazine analogues as mitochondrial therapeutic agents
US10364227B2 (en) 2015-02-17 2019-07-30 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
WO2016172187A1 (en) 2015-04-20 2016-10-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods and compositions related to kras inhibitors
US20180126013A1 (en) 2015-05-06 2018-05-10 H.Lee Moffitt Cancer Center And Research Institute, Inc. Radiotherapeutic and companion imaging agents to target mc1r
US10584108B2 (en) 2015-05-07 2020-03-10 Kuality Herbceutics Llc Therapeutic compounds and methods of use thereof
US10188704B2 (en) 2015-05-18 2019-01-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Enhanced melanoma cancer prevention by novel melanotropins
US11369569B2 (en) 2015-06-15 2022-06-28 University Of Virginia Patent Foundation Target-specific delivery of therapeutic agents
WO2016205534A1 (en) 2015-06-16 2016-12-22 Lazo John S Inhibitors of ptp4a3 for the treatment of cancer
US10814006B2 (en) 2015-07-14 2020-10-27 University Of Iowa Research Foundation Fluorescent prodrugs
EP3328372A4 (en) 2015-07-28 2019-03-20 University Of Iowa Research Foundation COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
US10336734B2 (en) 2015-08-02 2019-07-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibitors of ACK1/TNK2 tyrosine kinase
US10550124B2 (en) 2015-08-13 2020-02-04 San Diego State University Foundation Atropisomerism for increased kinase inhibitor selectivity
CA2997501C (en) 2015-09-04 2022-05-10 Janssen Pharmaceutica Nv Therapeutic compound for pain and synthesis thereof
KR102696432B1 (ko) 2015-10-01 2024-08-16 바이오크리스트파마슈티컬즈,인코포레이티드 인간 혈장 칼리크레인 저해제
BR112018006480A2 (pt) 2015-10-01 2018-10-09 Goleini Inc ?vetor, método de tratamento de uma doença ou condição, composição, combinação de um vetor, kit, uso de um vetor, método para a modulação in vivo da atividade eletrofisiológica de uma célula
WO2017066428A1 (en) 2015-10-13 2017-04-20 H. Lee Moffitt Cancer Center & Research Institute, Inc. Brd4-kinase inhibitors as cancer therapeutics
CA3004048A1 (en) 2015-11-03 2017-05-11 Regents Of The University Of Minnesota Cd200 inhibitors and methods of use thereof
KR20180113976A (ko) 2015-11-20 2018-10-17 센화 바이오사이언시즈 인코포레이티드 암을 치료하기 위한 테트라사이클릭 퀴놀론 유사체의 병행 요법
US9957282B2 (en) 2015-12-14 2018-05-01 Senhwa Biosciences, Inc. Crystalline forms of quinolone analogs and their salts
US9980951B2 (en) 2015-12-17 2018-05-29 University Of Iowa Research Foundation Image guided therapy for cancer
EP3393436B1 (en) 2015-12-21 2023-06-07 L'oreal Composition comprising alkylcellulose, incompatible hydrocarbon and silicone oils and method employing it
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
TWI854164B (zh) 2016-02-01 2024-09-01 美商百歐克斯製藥公司 苯并吡唑化合物及其類似物
WO2017156527A1 (en) 2016-03-11 2017-09-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase and janus kinase inhibitors for prevention of graft versus host disease
EP3429996A4 (en) 2016-03-16 2020-02-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. SMALL MOLECULES AGAINST CEREBLON TO IMPROVE THE FUNCTION OF EFFECTOR T CELLS
CA3018750A1 (en) 2016-03-22 2017-09-28 Regents Of The University Of Minnesota Combination for treating pain
US10759740B2 (en) 2016-03-24 2020-09-01 Rutgers, The State University Of New Jersey Antibacterial agents
CN109219610A (zh) 2016-04-04 2019-01-15 新泽西州立拉特格斯大学 拓扑异构酶毒物
US10551384B2 (en) 2016-04-07 2020-02-04 Rutgers, The State University Of New Jersey MTOR kinase mutations and methods of use thereof
WO2017184642A1 (en) 2016-04-18 2017-10-26 Morrow Kenneth Michael Isolation of plant extracts
JP2019514969A (ja) 2016-05-04 2019-06-06 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 分子イメージング及びがんの免疫療法のためのδオピオイド受容体標的化薬
US10899793B2 (en) 2016-05-27 2021-01-26 Regents Of The University Of Minnesota Melanocortin ligands and methods of use thereof
AU2017282659A1 (en) 2016-06-20 2019-02-07 Rutgers, The State University Of New Jersey Therapeutic compounds
AU2017281940C1 (en) 2016-06-24 2024-11-07 University Of Iowa Research Foundation Compositions and methods of treating melanoma
ES2937307T3 (es) 2016-07-26 2023-03-27 Univ Southern California Inhibición selectiva del bromodominio del BDF1 fúngico
US11390605B2 (en) 2016-08-25 2022-07-19 Arizona Board Of Regents On Behalf Of Arizona State University Substituted pyrimidine compounds as multifunctional radical quenchers and their uses
MX377365B (es) 2016-09-08 2025-03-10 Journey Medical Corp Composiciones y métodos para tratar rosácea y acné.
RU2019114964A (ru) 2016-10-17 2020-11-17 Дженентек, Инк. Терапевтические средства и способы их применения
US11124541B2 (en) 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
IL266223B2 (en) 2016-10-31 2024-04-01 Biocryst Pharm Inc Prodrugs of kallikrein inhibitors
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
BR112019010607B1 (pt) 2016-11-29 2023-10-31 University Of Iowa Research Foundation Uso de precursores de nad e composição compreendendo os referidos precursores
US10710957B2 (en) 2017-01-09 2020-07-14 University Of Central Florida Research Foundation, Inc. Motuporamine derivatives as antimicrobial agents and antibiotic enhancers against resistant gram-negative bacteria
EP3571183B1 (en) 2017-01-20 2024-03-06 The Regents of the University of California 3-(phenyl)-2-(aminomethyl)-1-phenyl-2-propen-1-one derivatives as inhibitors of the n-terminal domain of the androgen receptor for treating prostate cancer
US10238626B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10231947B2 (en) 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof
US10238655B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds
EP3573957B1 (en) 2017-01-24 2023-04-26 Rivara, Mirko Compositions and methods for blocking sodium channels
US10294264B2 (en) 2017-04-21 2019-05-21 Warsaw Orthopedic, Inc. Oxysterol-therapeutic agent derivative for bone healing
CA3063174A1 (en) 2017-05-12 2018-11-15 Innovus Pharmaceuticals, Inc. Therapeutic methods and compositions
US10434106B2 (en) 2017-05-19 2019-10-08 Warsaw Orthopedic, Inc. Oxysterol-statin compounds for bone growth
WO2018217757A1 (en) 2017-05-22 2018-11-29 University Of Virginia Patent Foundation Compositions and methods for preparing and using mitochondrial uncouplers
AR112027A1 (es) 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
WO2018237134A1 (en) 2017-06-23 2018-12-27 San Diego State University Research Foundation Atropisomerism for enhanced kinase inhibitor selectivity
CN111479805B (zh) 2017-08-29 2024-08-13 罗格斯新泽西州立大学 治疗性吲唑
EP4141117A1 (en) 2017-08-30 2023-03-01 Arizona Board of Regents on behalf of Arizona State University Rna nanostructures and methods of making and using rna nanostructures
CA3076233A1 (en) 2017-10-06 2019-04-11 Blue Therapeutics, Inc. Methods of treating acute or chronic pain
JOP20200076A1 (ar) 2017-10-16 2020-04-30 Aragon Pharmaceuticals Inc مضادات أندروجين لعلاج سرطان البروستاتا غير النقيلي المقاوم للاستئصال
WO2019100004A2 (en) 2017-11-17 2019-05-23 Cytogel Pharma, Llc Polymer agonists of mu opioid receptors
AU2018368453B2 (en) 2017-11-17 2024-05-30 The Board Of Trustees Of The University Of Illinois Cancer therapy by degrading dual MEK signaling
JP7226830B2 (ja) 2017-11-30 2023-02-21 サイトジェル ファーマ リミテッド ライアビリティ カンパニー 新規の鎮痛薬製剤処方及びその使用
WO2019140140A1 (en) 2018-01-10 2019-07-18 Arizona Board Of Regents On Behalf Of Arizona State University Rna-nanostructured double robots and methods of use thereof
US10738093B2 (en) 2018-01-25 2020-08-11 The Hong Kong University Of Science And Technology Discovery of cationic nonribosomal peptides as Gram-negative antibiotics through global genome mining
CN112118837B (zh) 2018-02-13 2024-07-09 罗格斯新泽西州立大学 抗菌剂：o-烷基氘化派洛宁
WO2019168688A2 (en) 2018-02-15 2019-09-06 Senhwa Biosciences, Inc. Quinolone analogs and their salts, compositions, and method for their use
US11890352B2 (en) 2018-02-27 2024-02-06 University Of Virginia Patent Foundation Plectin-targeted liposomes/PARP inhibitor in the treatment of cancer
WO2019173507A1 (en) 2018-03-06 2019-09-12 Rutgers, The State University Of New Jersey Antibacterial agents : arylalkylcarboxamido phloroglucinols
TWI873092B (zh) 2018-04-06 2025-02-21 美商百歐克斯製藥公司 取代的苯并呋喃、苯并吡咯、苯并噻吩及結構相關的補體抑制劑
BR112020021469A2 (pt) 2018-04-20 2021-01-19 Virginia Tech Intellectual Properties, Inc. Imidazopiridinas úteis como desacopladores mitocondriais
US12344845B2 (en) 2018-04-27 2025-07-01 Arizona Board Of Regents On Behalf Of Arizona State University Highly knotted molecular topologies from single-stranded nucleic acids
EP4556031A3 (en) 2018-04-27 2025-06-25 University of Iowa Research Foundation Compositions for chelating metals at low temperatures
US12239666B2 (en) 2018-06-19 2025-03-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inc. Oncolytic virus or antigen presenting cell mediated cancer therapy using type I interferon and CD40-ligand
US10758594B2 (en) 2018-06-26 2020-09-01 Marine Essence Biosciences Corporation of USA Biomaterial devices and topical compositions for treatment of skin abnormalities
US10912822B2 (en) 2018-06-26 2021-02-09 Marine Essence Biosciences Corporation of USA Biomaterial devices and topical compositions for guided tissue regeneration
SG11202012464WA (en) 2018-07-11 2021-01-28 H Lee Moffitt Cancer Center And Research Institute Inc Dimeric immuno-modulatory compounds against cereblon-based mechanisms
US10898460B1 (en) 2018-07-20 2021-01-26 University Of South Florida Leishmania inhibitors
US11987568B2 (en) 2018-08-03 2024-05-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Allosteric inhibitor of WEE1 kinase
JP7487949B2 (ja) 2018-08-09 2024-05-21 ザ ボード オブ トラスティーズ オブ ザ ユニバーシテイ オブ イリノイ イミダゾテトラジン化合物
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof
US12319685B2 (en) 2018-08-17 2025-06-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Small molecule pyrin-domain targeted NLRP3 inflammasome inhibitors
ES2906715T3 (es) * 2018-09-06 2022-04-20 Marine Essence Biosciences Corp Of Usa Dispositivos de biomaterial para la regeneración de tejidos guiada
US12162856B2 (en) 2018-10-18 2024-12-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. β-catenin and B-cell lymphoma 9 (BCL9) inhibitors
EP3877439A4 (en) 2018-11-07 2022-08-10 Regents of the University of Minnesota ANALGESIC AND ANTI-ADDICTION PROTECTIVE COMPOSITIONS FOR THE TREATMENT OF CHRONIC PAIN AND OPIOID ADDICTION
EP3887401A2 (en) 2018-11-26 2021-10-06 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
WO2020118179A1 (en) 2018-12-07 2020-06-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Peptidomimetic inhibitors of β-catenin/tcf protein–protein interaction
JP7663237B2 (ja) 2019-01-14 2025-04-16 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ がん免疫療法のためのｃｄ２００ａｒリガンド
US10889601B2 (en) 2019-02-11 2021-01-12 University Of Iowa Research Foundation Separations using boron containing hydrocarbon sponges
WO2020225779A1 (en) 2019-05-09 2020-11-12 Istituto Pasteur Italia - Fondazione Cenci Bolognetti Rig-i agonists for cancer treatment and immunotherapy
WO2020263989A1 (en) 2019-06-24 2020-12-30 University Of Iowa Research Foundation Jnk inhibitors as anticancer agents
US11840703B2 (en) 2019-07-01 2023-12-12 Matrexa LLC Recombinant versican isoforms and related compositions and methods
BR112022002060A2 (pt) 2019-08-06 2022-06-07 Biocryst Pharm Inc Síntese de escala de processo de um inibidor de calicreína de plasma
UY38912A (es) 2019-10-09 2021-05-31 Biocryst Pharm Inc Inhibidores del factor d del complemento para administración oral
US12234578B2 (en) 2020-01-29 2025-02-25 Wisconsin Alumni Research Foundation Tannin composite fibers
AR121715A1 (es) 2020-04-03 2022-06-29 Biocryst Pharm Inc Pirrolopirimidinaminas como inhibidores del sistema del complemento
WO2021211279A1 (en) 2020-04-17 2021-10-21 Regents Of The University Of Minnesota SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF
US12318469B2 (en) 2020-06-30 2025-06-03 L'oréal Cosmetic compositions capable of forming a multilayer structure after application to a keratinous material containing a combination of silicone resins
US11529335B2 (en) 2020-07-31 2022-12-20 University Of Iowa Research Foundation Compositions and methods for treating cancer
WO2022155332A1 (en) 2021-01-13 2022-07-21 Blue Therapeutics, Inc. Methods of treating irritable bowel syndrome
AU2022222781A1 (en) 2021-02-22 2023-08-24 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
US12303564B2 (en) 2021-03-19 2025-05-20 Wisconsin Alumni Research Foundation Composite chitosan-tannin-active agent compositions and methods of making and using same
JP2022151457A (ja) * 2021-03-26 2022-10-07 株式会社ピカソ美化学研究所 皮膚用組成物
US11780828B2 (en) 2021-05-04 2023-10-10 Regents Of The University Of Minnesota Contraceptive compounds and methods
US12447135B2 (en) 2021-10-11 2025-10-21 University Of South Florida Fenchol as a stimulator of free fatty acid receptor and other uses thereof
WO2023081237A1 (en) 2021-11-03 2023-05-11 Regents Of The University Of Minnesota Toll-like receptor agonists and antagonists and uses thereof
WO2023091689A1 (en) 2021-11-19 2023-05-25 University Of Iowa Research Foundation Combined use of mcr1-directed radiotherapy and immune checkpoint inhibition in the treatment of melanoma
WO2024006977A1 (en) 2022-07-01 2024-01-04 University Of Southern California Analgesic delta opioid receptor bitopic ligands
WO2024009283A1 (en) 2022-07-07 2024-01-11 University Of Southern California At2 antagonists for non-addictive pain relief
TW202409024A (zh) 2022-07-08 2024-03-01 美商愛克堤歐生物科學公司 治療性化合物及方法
EP4583912A2 (en) 2022-09-09 2025-07-16 Regents of the University of Minnesota Antibodies against fentanyl and analogs and methods of use thereof
WO2024102342A1 (en) 2022-11-10 2024-05-16 University Of Iowa Research Foundation Combination of a glutathione synthesis inhibitor such as buthionine sulphoximine and an immune checkpoint inhibitor, preferably pembrolizumab, to treat cancer, preferably drug-resistant melanoma
WO2024112932A1 (en) 2022-11-23 2024-05-30 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
CN120303249A (zh) 2022-12-07 2025-07-11 罗格斯新泽西州立大学 碳酸酐酶抑制剂及其使用方法
WO2024197165A1 (en) 2023-03-21 2024-09-26 University Of Iowa Research Foundation Broad spectrum antifungal keto-alkyl-pyridinium compounds
WO2024206284A2 (en) 2023-03-27 2024-10-03 Rutgers, The State University Of New Jersey Therapeutic compounds
WO2024226603A1 (en) 2023-04-24 2024-10-31 Regents Of The University Of Minnesota Therapeutic compounds

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2041594A5 (da) * 1969-04-30 1971-01-29 Expanscience
US4256664A (en) * 1973-03-12 1981-03-17 Colgate-Palmolive Company Substantive sunscreen agents
US4165385A (en) * 1973-05-29 1979-08-21 Dianis Creations, Inc. Water-in-oil emulsion for skin moisturizing
US4014995A (en) * 1973-09-19 1977-03-29 The Quaker Oats Company Cosmetics containing finely divided oat flour
US4380549A (en) * 1975-07-23 1983-04-19 Scott Eugene J Van Topical treatment of dry skin
GB2008943B (en) * 1977-11-26 1982-05-19 Beecham Group Ltd Cosmetic lotions
US4355028A (en) * 1978-04-04 1982-10-19 Westwood Pharmaceuticals, Inc. Composition for treating acne vulgaris
US4248861A (en) * 1979-02-21 1981-02-03 Schutt Steven R Skin treatment methods
US4233295A (en) * 1979-05-31 1980-11-11 E. R. Squibb & Sons, Inc. Corticosteroid formulations containing sebacate carrier
US4305936A (en) * 1980-10-09 1981-12-15 Dermik Laboratories Topical corticosteroid formulations
US4389418A (en) * 1981-02-25 1983-06-21 S. C. Johnson & Son, Inc. Skin care composition
LU83173A1 (fr) * 1981-02-27 1981-06-05 Oreal Nouvelles compositions cosmetiques pour le traitement des cheveux et de la peau contenant une poudre resultant de la pulverisation d'au moins une plante et un agent de cohesion
US4346086A (en) * 1981-06-09 1982-08-24 Beiersdorf Aktiengesellschaft Corticosteroid-containing cream
JPS588009A (ja) * 1981-07-08 1983-01-18 ギスト・ブロカデス・ナ−ムロ−ゼ・フエンノ−トチヤツプ 身体の局部療法のための組成物
US4382960A (en) * 1981-08-03 1983-05-10 Eli Lilly And Company Cosmetic cleanser formulation
US4368187A (en) * 1981-08-03 1983-01-11 Eli Lilly And Company Sensitive-skin care regime
US4368189A (en) * 1981-08-03 1983-01-11 Eli Lilly And Company Cosmetic moisturizer formulation
US4478853A (en) * 1982-05-17 1984-10-23 S. C. Johnson & Son, Inc. Skin conditioning composition
EP0103911A1 (en) * 1982-06-30 1984-03-28 THE PROCTER & GAMBLE COMPANY Emollient-containing topical pharmaceutical compositions
JPS59139315A (ja) * 1983-01-31 1984-08-10 Taisho Pharmaceut Co Ltd クリ−ム剤
JPS6038310A (ja) * 1983-08-11 1985-02-27 Kobayashi Kooc:Kk パ−ル剤組成物
US4563346A (en) * 1984-03-14 1986-01-07 Charles Of The Ritz Group Ltd. Topical delivery system and skin treatment compositions employing such system
DE3534743A1 (de) * 1985-09-28 1987-04-02 Beiersdorf Ag Hydrocortisondiester enthaltende o/w-creme

Also Published As

Publication number Publication date
ZA892366B (en) 1989-12-27
KR890015730A (ko) 1989-11-25
US4992478A (en) 1991-02-12
MX166589B (es) 1993-01-20
EP0336902A2 (en) 1989-10-11
AU3232889A (en) 1989-10-05
NO891380L (no) 1989-10-05
FI891593A0 (fi) 1989-04-03
JPH0215022A (ja) 1990-01-18
PT90197A (pt) 1989-11-10
NO891380D0 (no) 1989-03-31
NZ228564A (en) 1991-06-25
PT90197B (pt) 1994-06-30
FI891593A7 (fi) 1989-10-05
AU615042B2 (en) 1991-09-19
PH25897A (en) 1991-12-19
DK159689A (da) 1989-10-05
EP0336902A3 (en) 1991-05-29

Similar Documents

Publication Publication Date Title
DK159689D0 (da) Medikeret hudplejepraeparat, dets fremstilling og anvendelse
DK159989A (da) Hudplejepraeparat, dets fremstilling og anvendelse
DE3854275D1 (de) Äusserliches Hautpflegepräparat.
DK378687A (da) Laegemiddel, fremgangsmaade til dets fremstilling og anvendelse mod hiv-infektioner hos mennesker
DK656189A (da) Stabiliseret sucralosekompleks, dets fremstilling og anvendelse
NO890795L (no) Hudbehandlingspreparat.
NO178094C (no) Hudpleiepreparater
DK629989A (da) Oralt, antiseptisk middel, dets fremstilling og anvendelse samt produkter, hvori det indgaar
NO905421D0 (no) Kosmetiske og hudbehandlingsblandinger.
DK170887D0 (da) Aromatiske forbindelser, deres fremstilling og deres anvendelse til human- og veterinaermedicinske og kosmetiske formaal
NO883542L (no) Haarkosmetisk middel og fremgangsmaate for dets fremstilling
NO891006D0 (no) Terapeutisk aktivt polypeptid og fremgangsmaate for dets fremstilling.
DK39888D0 (da) Stabilt thrombinpraeparat, dets fremstilling og anvendelse
DK525687A (da) Enzymholdigt praeparat, dets fremstilling og anvendelse
FI914939A7 (fi) Valmiste kynsien-, ihon- ja hiustenhoitoa varten
FI895286A7 (fi) Fenyylioksipropanoliamineja, niiden valmistus ja terapeuttinen käyttö
DK115389A (da) Applikator til hudrensemiddel, hudplejemiddel og medicinsk indgnidningsmiddel
DK173886A (da) 1-hydroxy-8-acyloxy-10-acyl-anthroner, deres fremstilling og deres anvendelse til human- eller veterinaermedicinske og kosmetiske formaal
DK587588A (da) Polypeptid, dets anvendelse og fremstilling
DK420889A (da) Farmaceutisk kombinationspraeparat, dets fremstilling og anvendelse
DK587688A (da) Polypeptid, dets anvendelse og fremstilling
NO874932D0 (no) Middel med rensende og hudpleiende egenskaper.
DK501689A (da) Cumarinderivat, dets fremstilling og anvendelse
BR6900691U (pt) Colchao ortopedico e medicinal
PT7956Y (pt) Colchao ortopedico e medicinal

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment
PBP Patent lapsed